Evaluation of the Effect of Everolimus on Retinal Pigment Epithelial Cells and Experimental Proliferative Vitreoretinopathy

References

• Chignell AH, Fison LG, Davies EW, Hartley RE, Gundry MF. Failure in retinal detachment surgery. Br J Ophthalmol. 1973;57:525–30.
   PubMed Web of Science ®Google Scholar
• Heimann H, Bartz-Schmidt KU, Bornfeld N, Weiss C, Hilgers RD, Foerster MH. Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment: a prospective randomized multicenter clinical study. Ophthalmology. 2007;114:2142–54.
   PubMed Web of Science ®Google Scholar
• Falkner-Radler CI, Myung JS, Moussa S, Chan RVP, Smretschnig E, Kiss S, et al. Trends in primary retinal detachment surgery. Results of a bicenter study. Retina. 2011;31:928–36.
   PubMed Web of Science ®Google Scholar
• Leiderman YI, Miller JW. Proliferative vitreoretinopathy: pathobiology and therapeutic targets. Semin Ophthalmol. 2009;24:62–69.
   PubMed Web of Science ®Google Scholar
• Clarkson JG, Green WR, Massof D. A histopathologic review of 168 cases of preretinal membrane. Am J Ophthalmol. 1977;84:1–17.
   PubMed Web of Science ®Google Scholar
• Machemer R, Van Horn D, Aaberg TM. Pigment epithelial proliferation in human retinal detachment with massive periretinal proliferation. Am J Ophthalmol. 1978;85:181–91.
   PubMed Web of Science ®Google Scholar
• Morino I, Hiscott P, McKechnie N, Grierson I. Variation in epiretinal membrane components with clinical duration of the proliferative tissue. Br J Ophthalmol. 1990;74:393–99.
   PubMed Web of Science ®Google Scholar
• Vinores SA, Campochiaro PA, Conway BP. Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Invest Ophthalmol Vis Sci. 1990;31:14–28.
   PubMed Web of Science ®Google Scholar
• Sethi CS, Lewis GP, Fisher SK, Leitner WP, Mann DL, Luthert PJ, et al. Glial remodeling and neural plasticity in human retinal detachment with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2005;46:329–42.
   PubMed Web of Science ®Google Scholar
• Fisher SK, Erickson PA, Lewis GP, Anderson DH. Intraretinal proliferation induced by retinal detachment. Invest Ophthalmol Vis Sci. 1991;32:1739–48.
   PubMed Web of Science ®Google Scholar
• Nakazawa T, Takeda M, Lewis GP, Cho KS, Jiao J, Wilhelmsson U, et al. Attenuated glial reactions and photoreceptor degeneration after retinal detachment in mice deficient in glial fibrillary acidic protein and vimentin. Invest Ophthalmol Vis Sci. 2007;48:2760–68.
   PubMed Web of Science ®Google Scholar
• Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108:1179–83.
   PubMed Web of Science ®Google Scholar
• Daniels SA, Coonley KG, Yoshizumi MO. Taxol treatment of experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1990;228:513–16.
   PubMed Web of Science ®Google Scholar
• Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferation with intravitreal corticosteroids. Am J Ophthalmol. 1980;89:131–36.
   PubMed Web of Science ®Google Scholar
• Kirmani M, Santana M, Sorgente N, Wiedemann P, Ryan SJ. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy. Retina. 1983;3:269–72.
   PubMed Web of Science ®Google Scholar
• Kuo HK, Wu PC, Yang PM, Chen YH, Wu YC, Hu DN. Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy. J Ocul Pharmacol Ther. 2007;23:14–20.
   PubMed Web of Science ®Google Scholar
• Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol. 1998;126:550–59.
   PubMed Web of Science ®Google Scholar
• Kuo HK, Chen YH, Wu PC, Wu YC, Huang F, Kuo CW, et al. Attenuated glial reaction in experimental proliferative vitreoretinopathy treated with liposomal doxorubicin. Invest Ophthalmol Vis Sci. 2012;53:3167–74.
   PubMedGoogle Scholar
• Klumpen HJ, Beijnen JH, Gurney H, Schellens JHM. Inhibitors of mTOR. The Oncologist. 2010;15:1262–69.
   PubMed Web of Science ®Google Scholar
• Zhou P, Zhao MW, Li XX, Yu WZ, Bian ZM. siRNA targeting mammallian taget of rapamycin (mTOR) attenuates experimental proliferative vitreoretinopathy. Curr Eye Res. 2007;32:973–84.
   PubMed Web of Science ®Google Scholar
• Lewis GP, Chapin EA, Byun J, Luna G, Sherris D, Fisher SK. Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway. Invest Ophthalmol Vis Sci. 2009;50:4429–35.
   PubMed Web of Science ®Google Scholar
• Houghton PJ. Everolimus. Clin Cancer Res. 2010;16:1368–72.
   PubMed Web of Science ®Google Scholar
• Hirt SW, Bara C, Barten MJ, Deuse T, Doesch AO, Kaczmarek I, et al. Everolimus in heart transplantation: an update. J Transplant. 2013;2013:683964.
   PubMedGoogle Scholar
• Baetta R, Granata A, Canavesi M, Ferri N, Arnaboldi L, Bellosta S, et al. Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. J Pharmacol Exp Ther. 2009;328:419–25.
   PubMed Web of Science ®Google Scholar
• Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes D, et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv. 2012;5:357–64.
   PubMed Web of Science ®Google Scholar
• Toyota T, Shiomi H, Morimoto T, Kimura T. Meta-analysis of long-term clinical outcomes of everolimus-eluting stents. Am J Cardiol. 2015;116:187–94.
   PubMed Web of Science ®Google Scholar
• Hennig M, Bauer D, Wasmuth S, Busch M, Walscheid K, Thanos S, et al. Everolimus improves experimental autoimmune uveoretinitis. Exp Eye Res. 2012;105:43–52.
   PubMed Web of Science ®Google Scholar
• Yagasaki R, Nakahara T, Ushikubo H, Mori A, Sakamoto K, Ishii K. Anti-angiogenic effects of mammaliant target of rapamycin inhibitors in a mouse model of oxygen-induced retinopathy. Biol Pharm Bull. 2014;37:1838–42.
   PubMed Web of Science ®Google Scholar
• Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O’Reilly T, Evans DB, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005;11:5319–28.
   PubMed Web of Science ®Google Scholar
• Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, et al. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer. 2009;16:1017–27.
   PubMed Web of Science ®Google Scholar
• Amirouchene-Angelozzi N, Nemati F, Gentien D, Nicolas A, Dumont A, Carita G, et al. Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target. Mol Oncol. 2014;8:1508–20.
   PubMed Web of Science ®Google Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83–95.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008;26:1603–10.
   PubMed Web of Science ®Google Scholar
• Huang K, Fingar DC. Growing knowledge of the mTOR signaling network. Semin Cell Dev Biol. 2014 December;36:79–90.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Loh K, Yap YS. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2015;12:342–54.
   PubMed Web of Science ®Google Scholar
• Francipane MG, Lagasse E. mTOR pathway in colorectal cancer: an update. Oncotarge. 2014 Jan 15;5(1):49–66.
   PubMed Web of Science ®Google Scholar
• Xie J, Wang X, Proud CG. mTOR inhibitors in cancer therapy. F1000Res. 2016;5(F1000Faculty Rev):2078.
   Google Scholar
• Amirouchene-Angelozzi N, Frisch-Dit-Leitz E, Carita G, Dahmani A, Raymondie C, Liot G, Gentien D, Némati F, Decaudin D, Roman-Roman S, et al. The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma. Oncotarget. 2016 Apr 26;7(17):23633–46.
   PubMed Web of Science ®Google Scholar
• Ryan SJ. Traction retinal detachment. XLIX Edward Jackson memorial lecture. Am J Ophthalmol. 1993;115:1–20.
   PubMed Web of Science ®Google Scholar
• Weller M, Wiedemann P, Heimann K. Proliferative vitreoretinopathy— is it anything more than wound healing at the wrong place? Int Ophthalmol. 1990;14:105–17.
   PubMed Web of Science ®Google Scholar
• Kuo HK, Chen YH, Wu PC, Kuo YH. The effects of Ozurdex® (Dexamethasone intravitreal implant) on experimental proliferative vitreoretinopathy. Ophthalmologica. 2015;233:198–203.
   PubMed Web of Science ®Google Scholar
• Khan MA, Brady CJ, Kaiser RS. Clinical management of proliferative vitreoretinopathy: an update. Retina. 2015;35:165–75.
   PubMed Web of Science ®Google Scholar
• Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3–18.
   PubMed Web of Science ®Google Scholar